Guidelines

O.4 In vitro generation of tumor antigen-specific T cells from patient and healthy donor stem cells

February 2017
O.5 Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): an interim analysis from the Belgian Hematology Society (BHS)

February 2017
O.6 Successful Transition from paediatric to adult care in Sickle Cell Disease: An Experience in a Belgian Center

February 2017
PP01 Mucosal- associated invariant T cells deficiency in multiple myeloma can be overcome by PD-1 inhibition

February 2017
PP02 The histone methyltransferases G9a/GLP: new promising targets for the treatment of multiple myeloma

February 2017
PP03 The anaphase-promoting-complex/ cyclosome: a new promising target in mantle cell lymphoma and diffuse large B cell lymphoma

February 2017
PP04 Light chain IgLV3-21 is associated with poor prognosis in Chronic Lymphocytic Leukemia patients independently of the presence of heavy chain IgHV3-21

February 2017
PP05 The detection rate of PET/CT after co-administration of [18F]NaF and [18F]FDG is superior to the detection rate of whole-body MRI in the diagnosis of MM lesions

February 2017
PP30 Retrospective study of de novo and secondary myeloid sarcoma

February 2017
PP31 Roles of microRNAs in myeloid malignancies driven by activated tyrosine kinases

February 2017

Top